Abstracts
Purpose: Decrease the number of unanticipated patient returns following Percutaneous Endoscopic Gastrostomy (PEG) tube placement to an outpatient gastroenterology endoscopy center. Methods: A quality and process improvement team was created and met bi-weekly for six months to address this issue. Patients with newly placed PEG tubes from October 2010 to October 2011 were identifi ed. Chart review indicated that 10 of 50 (20%) patients had an unanticipated return to the endoscopy center post-PEG placement. Causes for the returns were tight bumper, cellulitis, fever, tube cap dysfunction, clogged tubes, nausea, vomiting, constipation and intentional or inadvertent removal. Quality improvement analysis tools such as brainstorming, fl owchart, fi shbone diagram, Pareto diagram, and statistical process chart analysis were used to identify the cause for returns and to identify opportunities for improvement. Th e analysis indicated that there was a lack of education provided to patients both prior and post PEG placement. Th erefore, a PEG tube education guide was created, approved and implemented. Th e bilingual educational pamphlet met the requirements of the hospital's patient education committee by ensuring that the pamphlet was at grade 3-5th grade reading level. A designated phone number as fi rst point of contact in case of gastrostomy complications was provided on the pamphlet at patient discharge to decrease unanticipated returns to the outpatient gastroenterology endoscopy center. In addition to these process improvements, a protocol was implemented to standardize verbal counseling and protocol incoming patient calls regarding PEG issues and care. Results: Since the implementation of the PEG patient education handout, we have not had an unanticipated patient return. Conclusion: Educating patients and their caregivers on the care of gastrostomy tubes both pre-and post-procedure is essential. Providing and implementing a protocol along with providing patients with a comprehensive pamphlet will reduce post-PEG placed complications and returns in an outpatient endoscopy center. In addition, our project indicates that quality and process improvement analysis tools can help to improve patient care. Purpose: Upper gastrointestinal bleeding (UGIB) is common, with an annual incidence of 1 per 1,000 population. Th e mortality from UGIB ranges from 3-14%; rebleeding despite endoscopic therapy occurs in 7-16% of cases. ICU management is advisable for severe UGIB, and especially for suspected bleeding varices, but may not be always necessary. Th e aims of this study were to determine diff erences in presentation, management and outcome between cases triaged to an ICU versus a regular fl oor. Methods: A retrospective chart review from a tertiary care referral center. All patients >18 years admitted between August 2010 -July 2011 with either an admission or discharge diagnosis of acute UGIB were included. Patients were then classifi ed based on their location of initial admission (ICU versus fl oor) and their demographic, clinical characteristics, management and outcomes were compared. Results: A total of 289 patients were identifi ed. Th eir mean (range) age was 62 (18-98) years; 61% were male. Triage by emergency room physicians resulted in 96 patients being admitted to ICU and 193 patients to the fl oor. Th e presenting characteristics of these patients are in Table 1 . Adverse outcomes, defi ned as death, transition to hospice care or a rebleed during hospitalization or within 30 days of discharge, were noted in 12.8% of the admissions for UGIB. An EGD was performed in 86% of cases and blood was transfused in 68.5% of the patients. Ninety-eight percent of ICU patients had an EGD and 99% had blood transfused, which was signifi cantly higher than the fl oor group (p=<0.0001).
[Image] Average length of stay and cost of hospitalization were 5 (1-62) days and $32,970 $(3,077-582,041), respectively. Table 2 shows the differences in management and outcomes. Conclusion: Patients admitted to the ICU were sicker, with more frequent melena and hematemesis, lower BP, higher heart rate, lower hemoglobin, and higher BUN and INR. Risk stratifi cation scores confi rmed these observations. Th e 2 groups did not diff er in their comorbidities. In spite of prompt endoscopy with interventions and aggressive transfusions, cases admitted to the ICU had more adverse outcomes and longer and more costly hospitalizations.
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Predictors of Fatigue Severity among Treatment-Naïve Genotype 1 Chronic Hepatitis C Patients: Post-Hoc Analyses of Data from ADVANCE and ILLUMINATE
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Rockall Score (mean, range) 5.6 (1 -10) 3.5 (0 -8) 0.0001
Blatchford score (mean, range) 12 (1 -18) 7.5 (0 -17) 0.0001 Time of EGD from admit indays (mean, range)
